Background: Spinal metastases can cause significant impairment of neurological function and quality of life. Hence, personalized clinical decision-making based on prognosis and likely outcome is desirable. The effectiveness of AI in predicting complications and treatment outcomes for patients with spinal metastases is assessed. Methods: A thorough search was carried out through the PubMed, Scopus, Web of Science, Embase, and Cochrane databases up until 27 January 2025. Included were studies that used AI-based models to predict outcomes for adult patients with spinal metastases. Three reviewers independently extracted the data, and screening was conducted in accordance with PRISMA principles. AUC results were pooled using a random-effects model, and the PROBAST program was used to evaluate the study’s quality. Results: Included were 47 articles totaling 25,790 patients. For training, internal validation, and external validation, the weighted average AUCs were 0.762, 0.876, and 0.810, respectively. The Skeletal Oncology Research Group machine learning algorithms (SORG-MLAs) were the ones externally validated the most, continuously producing AUCs > 0.84 for 90-day and 1-year mortality. Models based on radiomics showed promise in preoperative planning, especially for outcomes of radiation and concealed blood loss. Most research concentrated on breast, lung, and prostate malignancies, which limited its applicability to less common tumors. Conclusions: AI models have shown reasonable accuracy in predicting mortality, ambulatory status, blood loss, and surgical complications in patients with spinal metastases. Wider implementation necessitates additional validation, data standardization, and ethical and regulatory framework evaluation. Future work should concentrate on creating multimodal, hybrid models and assessing their practical applications.
Sanker et al. (Wed,) studied this question.